Jeetinder Singh Mahal - Jun 12, 2024 Form 4 Insider Report for Jasper Therapeutics, Inc. (JSPR)

Role
Chief Operating Officer
Signature
/s/ Jeet Mahal
Stock symbol
JSPR
Transactions as of
Jun 12, 2024
Transactions value $
-$15,350
Form type
4
Date filed
6/12/2024, 09:40 PM
Previous filing
Mar 12, 2024
Next filing
Sep 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JSPR Voting Common Stock Options Exercise $6.39K +900 +3.6% $7.10 25.9K Jun 12, 2024 Direct F1
transaction JSPR Voting Common Stock Sale -$21.7K -900 -3.47% $24.16 25K Jun 12, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JSPR Stock Option (right to buy) Options Exercise $0 +900 +6.13% $0.00 15.6K Jun 12, 2024 Voting Common Stock 900 $7.10 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.975 to $24.555, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
F3 25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares subject to the option vested monthly thereafter.

Remarks:

Exhibit 24 - Power of Attorney